Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Salvage CLAM Chemotherapy and PBSC Infusion for Acute Leukemia Relapse After Allo-HSCT
NCT02910752Phase 2Suspended
- Sponsor
- Shanghai Jiao Tong University School of Medicine
- Start
- Sep 2016
- Primary completion
- Sep 2023
- Modality
- DNA Intercalators/Alkylators, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of cladribine, cytarabine, mitoxantrone, peripheral blood stem cells in acute leukemia, sponsored by Shanghai Jiao Tong University School of Medicine. Started Sep 2016; status: suspended.
02
Drugs
cladribinecytarabinemitoxantroneperipheral blood stem cells
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT02910752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02910752.